NCT06617715View on ClinicalTrials.gov

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

PHASE3RecruitingINTERVENTIONAL
Enrollment

3,080

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

October 12, 2025

Study Completion Date

April 12, 2026

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Sinovac PCV13

One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.

BIOLOGICAL

Prevnar®

One dose of Prevnar® (0.5 mL) is administered intramuscularly.

Trial Locations (1)

Unknown

RECRUITING

Henan Provincial Center for Disease Control and Prevention, Zhengzhou

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY